glp 1 drugs and ulcerative colitis Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential GLP-1 based therapies and disease
Description
Almost three decades ago, the discovery of leptin triggered a new era of molecular obesity research
10.1111/obr.12334 4
Kivimki, M
Further studies on RGC in relation to the time of the last dose of GLP-1 agonists also have varying results, making set timeframes to stop the use of GLP-1 s preoperatively difficult to determine (Santos et al
